Pfizer locks in long runway for blockbuster heart drug after key patent settlements

The deals, tied to cases in the US District Court for the District of Delaware, effectively extend US patent protection for VYNDAMAX until June 1, 2031

Metropolis Healthcare launches blood-based test for early Alzheimer’s detection

New minimally invasive biomarker test enables earlier diagnosis and improved clinical decision-making, aligned with global guidelines

C2N Diagnostics expands Alzheimer’s blood test to South Korea via BeauBrain partnership

Under the agreement, healthcare professionals in the country will gain access to C2N’s PrecivityAD2 blood test

Mahajan Imaging & Labs launches AI-driven blood test to detect Alzheimer’s early

Over 8.8?million Indians aged 60 and above currently live with dementia,

Novo Nordisk’s Semaglutide fails to slow Alzheimer’s progression in Phase 3 trials

The trials, designed to assess whether semaglutide could slow cognitive decline, showed no significant difference compared to placebo in the progression of Alzheimer’s disease over two years

Quest Diagnostics’ study confirms accuracy of blood tests for Alzheimer’s disease diagnosis

Quest Diagnostics’ blood-based test panels demonstrate confirmatory accuracy, potentially reducing the need for PET imaging

Roche’s Elecsys pTau181 becomes first FDA-cleared blood test to rule out Alzheimer’s pathology in primary care

New test expands access to early Alzheimer’s assessment, streamlining diagnostic pathways and improving referral efficiency

BMS’s anti-MTBR-Tau granted fast track designation by FDA for Alzheimer’s disease

Anti-microtubule binding region-tau antibody being investigated as a potential disease-modifying therapy to slow or delay progression of disease

Leqembi wins NMPA nod for once-monthly IV dosing in early Alzheimer’s patients

LEQEMBI was initially approved in China in January 2024 for the treatment of Alzheimer’s disease in patients with mild cognitive impairment

European Commission approves Lilly’s Kisunla for treatment of early Alzheimer’s patients